{"id":250103,"date":"2023-01-12T00:00:00","date_gmt":"2023-01-12T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidim0128-biopharma-sjogrens-syndrome-epidemiology-emerging\/"},"modified":"2026-03-31T10:35:09","modified_gmt":"2026-03-31T10:35:09","slug":"epidim0128-biopharma-sjogrens-syndrome-epidemiology-emerging-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidim0128-biopharma-sjogrens-syndrome-epidemiology-emerging-markets\/","title":{"rendered":"Sjogren&#8217;s Syndrome &#8211; Epidemiology &#8211; Emerging Markets"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of Sjogren\u2019s syndrome (<abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr>) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy in the developed world.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>Of all people diagnosed with <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr>, how many in each country in the developed world are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to <span class=\"abbreviation-guard\">MS<\/span> Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts 15 <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr> patient populations, as follows:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed prevalent cases of <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr>.<\/li>\n<li>Diagnosed prevalent cases of primary <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr>.<\/li>\n<li>Diagnosed prevalent cases of secondary <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr>.<\/li>\n<li>Diagnosed incident cases of <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr>.<\/li>\n<li>Diagnosed incident cases of primary <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr>.<\/li>\n<li>Diagnosed incident cases of secondary <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr>.<\/li>\n<li>Diagnosed prevalent cases of primary <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr> with lymphoma.<\/li>\n<li>Diagnosed prevalent cases of primary <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr> without lymphoma.<\/li>\n<li>Diagnosed prevalent cases of primary <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr> with fibromyalgia.<\/li>\n<li>Diagnosed prevalent cases of primary <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr> without fibromyalgia.<\/li>\n<li>Diagnosed prevalent cases of secondary <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr> with systemic lupus erythematosus (<abbr title=\"systemic lupus erythematosus\">SLE<\/abbr>).<\/li>\n<li>Diagnosed prevalent cases of secondary <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr> with rheumatoid arthritis (<abbr title=\"rheumatoid arthritis\">RA<\/abbr>).<\/li>\n<li>Diagnosed prevalent cases of secondary <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr> with other autoimmune diseases.<\/li>\n<li>Diagnosed drug-treated prevalent cases of <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr>.<\/li>\n<li>Diagnosed non-drug-treated prevalent cases of <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr>.<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-250103","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-rheumatology","biopharma-therapy-areas-sjogrens-syndrome","biopharma-product-epidemiology","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250103","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250103\/revisions"}],"predecessor-version":[{"id":281874,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250103\/revisions\/281874"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=250103"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}